Chronic Pain Clinical Trials Epilepsy Packaging 
Cannabis Law Report
APRIL 10, 2019
MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.
Cannabis Law Report
NOVEMBER 10, 2021
The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 15, 2021
Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.
Cannabis Law Report
OCTOBER 17, 2019
Selinger cites software, point-of-sale systems, and packaging as areas that are thriving in the state. Some of the regulatory controls include limits on THC, packaging and labeling requirements, and products that cannot be combined with THC (e.g., Colorado has legalized both recreational and medical use of cannabis.
Cannabis Law Report
DECEMBER 30, 2019
For the first time, the FY 2020 Appropriations package contained this protection for 47 states within the base language of the text. Included in the final FY 2020 spending package). Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.
Expert insights. Personalized for you.
51 
Let's personalize your content